CD19 and neoplasm: While on‐target/off‐tumor toxicity of CAR‐T cell therapy may be acceptable in certain haematologic malignancies, such as hypogammaglobulinaemia observed after CD19‐CAR‐T cell therapy, it has hindered the development of CAR‐T cells for treating solid tumors and can be life‐threatening in a few cases.